Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novavax : Publishes Results From Late-Stage Influenza Vaccine Trial in The Lancet Infectious Diseases

09/24/2021 | 06:21am EDT


© MT Newswires 2021
All news about NOVAVAX, INC.
10/22INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claims Against ..
BU
10/22INVESTOR ALERT : Law Offices of Howard G. Smith Announces Investigation of Novavax, Inc. (..
BU
10/21INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims Against Nov..
BU
10/21GLANCY PRONGAY & MURRAY LLP : a Leading Securities Fraud Law Firm, Announces Investigation..
BU
10/21INSIDER SELL : Novavax
MT
10/21NOVAVAX : HAGENS BERMAN, NATIONAL TRIAL ATTOREYS, Encourages Novavax (NVAX) Investors with..
PR
10/21NOVAVAX : Reconfirms Confidence in Regulatory Filing Timelines and Manufacturing Quality
AQ
10/20Health Care Up On Defensive Bias -- Health Care Roundup
DJ
10/20SOCIAL BUZZ : Pinterest, ContextLogic, Novavax Most Active Wallstreetbets Stocks in Aftern..
MT
10/20Top Midday Decliners
MT
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Financials (USD)
Sales 2021 1 984 M - -
Net income 2021 -581 M - -
Net cash 2021 714 M - -
P/E ratio 2021 -16,7x
Yield 2021 -
Capitalization 10 023 M 10 023 M -
EV / Sales 2021 4,69x
EV / Sales 2022 1,37x
Nbr of Employees 792
Free-Float 98,7%
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 134,56 $
Average target price 264,20 $
Spread / Average Target 96,3%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.20.67%10 023
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455